• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

共病可预测生物标志物确诊的阿尔茨海默病患者的机构收容情况和死亡率。

Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer's disease.

作者信息

Xia Xin, Clark Alice, Brogaard Niels Juul, Mourer Alex, Areovimata Anna, Eriksdotter Maria, Zetterberg Henrik, Kern Silke, Skillbäck Tobias, Jönsson Linus

机构信息

Department of Neurobiology, Care Sciences and Society, Section for Neurogeriatrics, Karolinska Institutet, Solna, Sweden.

Karolinska Institutet, Solnavägen 30, floor 10, BioClinicum, Solna, 171 64, Sweden.

出版信息

Alzheimers Res Ther. 2025 Jul 12;17(1):155. doi: 10.1186/s13195-025-01807-6.

DOI:10.1186/s13195-025-01807-6
PMID:40646652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12255059/
Abstract

BACKGROUND

We explored the associations of comorbidities with cognitive deterioration, institutionalization, and mortality in biomarker-confirmed Alzheimer’s disease (AD) dementia.

METHODS

We conducted a Swedish Register-based cohort study consisting of 10,857 people (mean age 74 years) with diagnosed dementia and positive AD biomarkers (CSF Aβ/P-tau ratio). Cognitive function was measured by mini-mental state examination (MMSE). Comorbidities by human body organ systems (e.g., diseases of the circulatory system) and six selected comorbidities: type-2 diabetes (T2DM), ischemic heart disease (IHD), stroke, chronic kidney disease (CKD), inflammatory bowel disease, and depression, were analyzed. Multistate Cox regressions assessed the associations of comorbidities with cognitive deterioration, institutionalization, and death.

RESULTS

Only T2DM and IHD were associated with cognitive deterioration. Mental disorders, T2DM, and stroke were linked to higher hazards of institutionalization. Endocrine-metabolic disorders, circulatory system diseases, and CKD were associated with higher mortality rates.

CONCLUSIONS

Comorbidities may help inform the prognosis of biomarker-confirmed AD dementia.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1186/s13195-025-01807-6.

摘要

背景

我们探讨了共病与生物标志物确诊的阿尔茨海默病(AD)痴呆患者认知功能衰退、入住养老院及死亡率之间的关联。

方法

我们开展了一项基于瑞典登记册的队列研究,纳入了10857名(平均年龄74岁)已确诊痴呆且AD生物标志物(脑脊液Aβ/P-tau比值)呈阳性的患者。通过简易精神状态检查表(MMSE)评估认知功能。分析了按人体器官系统分类的共病情况(如循环系统疾病)以及六种选定的共病:2型糖尿病(T2DM)、缺血性心脏病(IHD)、中风、慢性肾脏病(CKD)、炎症性肠病和抑郁症。多状态Cox回归分析评估了共病与认知功能衰退、入住养老院及死亡之间的关联。

结果

仅T2DM和IHD与认知功能衰退相关。精神障碍、T2DM和中风与入住养老院的较高风险相关。内分泌代谢紊乱、循环系统疾病和CKD与较高死亡率相关。

结论

共病情况可能有助于了解生物标志物确诊的AD痴呆的预后。

补充信息

在线版本包含可在10.1186/s13195-025-01807-6获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/bc30e8f9544f/13195_2025_1807_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/d33a5b5aa6a2/13195_2025_1807_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/6f7655a629d3/13195_2025_1807_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/bc30e8f9544f/13195_2025_1807_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/d33a5b5aa6a2/13195_2025_1807_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/6f7655a629d3/13195_2025_1807_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754e/12255059/bc30e8f9544f/13195_2025_1807_Fig3_HTML.jpg

相似文献

1
Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer's disease.共病可预测生物标志物确诊的阿尔茨海默病患者的机构收容情况和死亡率。
Alzheimers Res Ther. 2025 Jul 12;17(1):155. doi: 10.1186/s13195-025-01807-6.
2
Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease.阿尔茨海默病全谱患者机构化和死亡的多变量预测模型的开发。
Alzheimers Res Ther. 2022 Aug 5;14(1):110. doi: 10.1186/s13195-022-01053-0.
3
The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study.衰弱和共病对痴呆患者住院和死亡的影响:一项前瞻性队列研究。
J Am Med Dir Assoc. 2019 Feb;20(2):165-170.e2. doi: 10.1016/j.jamda.2018.06.020. Epub 2018 Aug 23.
4
Nimodipine for primary degenerative, mixed and vascular dementia.尼莫地平用于原发性退行性、混合型和血管性痴呆。
Cochrane Database Syst Rev. 2000;2002(2):CD000147. doi: 10.1002/14651858.CD000147.
5
Nimodipine for primary degenerative, mixed and vascular dementia.尼莫地平用于原发性退行性、混合型和血管性痴呆。
Cochrane Database Syst Rev. 2001(1):CD000147. doi: 10.1002/14651858.CD000147.
6
Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.阿尔茨海默病新诊断患者的经济负担、死亡率和住院率。
J Alzheimers Dis. 2018;61(1):185-193. doi: 10.3233/JAD-170518.
7
Sex-specific association of comorbid heart failure on mortality after Alzheimer's disease diagnosis in older adults aged 75 years and above: A health insurance claims data analysis in Japan.75岁及以上老年人阿尔茨海默病诊断后合并心力衰竭与死亡率的性别特异性关联:日本医疗保险理赔数据分析
J Alzheimers Dis. 2025 Feb;103(3):749-757. doi: 10.1177/13872877241305813. Epub 2025 Jan 10.
8
Stress hyperglycemia ratio as a biomarker for early mortality risk stratification in cardiovascular disease: a propensity-matched analysis.应激性高血糖比值作为心血管疾病早期死亡风险分层的生物标志物:一项倾向匹配分析。
Cardiovasc Diabetol. 2025 Jul 12;24(1):286. doi: 10.1186/s12933-025-02812-7.
9
An artificial intelligence-derived metabolic network predicts psychosis in Alzheimer's disease.人工智能衍生的代谢网络可预测阿尔茨海默病中的精神病。
Brain Commun. 2025 Apr 25;7(3):fcaf159. doi: 10.1093/braincomms/fcaf159. eCollection 2025.
10
Frailty Index and Incident Mortality, Hospitalization, and Institutionalization in Alzheimer's Disease: Data From the ICTUS Study.衰弱指数与阿尔茨海默病患者的死亡率、住院率及机构化:来自ICTUS研究的数据
J Gerontol A Biol Sci Med Sci. 2016 Apr;71(4):543-8. doi: 10.1093/gerona/glv137. Epub 2015 Aug 13.

本文引用的文献

1
Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.需要在阿尔茨海默病治疗方面取得进展——欧洲阿尔茨海默病联合会(EADC)研究人员的立场声明。
J Prev Alzheimers Dis. 2024;11(5):1212-1218. doi: 10.14283/jpad.2024.153.
2
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.《痴呆症的预防、干预与照护:柳叶刀常设委员会2024年报告》
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
3
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.
抗淀粉样蛋白治疗的资格:为阿尔茨海默病的疾病修饰疗法做准备。
J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):796-803. doi: 10.1136/jnnp-2024-333468.
4
2024 Alzheimer's disease facts and figures.2024 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.
5
Distinguishing features of depression in dementia from primary psychiatric disease.痴呆症中抑郁症与原发性精神疾病的鉴别特征。
Discov Ment Health. 2024 Jan 4;4(1):3. doi: 10.1007/s44192-023-00057-y.
6
Multimorbidity Pattern and Risk for Mortality Among Patients With Dementia: A Nationwide Cohort Study Using Latent Class Analysis.痴呆患者的共病模式与死亡风险:一项使用潜在类别分析的全国性队列研究。
Psychiatry Investig. 2023 Sep;20(9):861-869. doi: 10.30773/pi.2023.0112. Epub 2023 Sep 19.
7
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
8
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗:合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
9
Effect of Comorbidities on Ten-Year Survival in Patients with Dementia.合并症对痴呆症患者十年生存率的影响。
J Alzheimers Dis. 2023;94(1):163-175. doi: 10.3233/JAD-221259.
10
Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis.社区环境中成年人群体多重疾病的全球和区域患病率:一项系统评价和荟萃分析。
EClinicalMedicine. 2023 Feb 16;57:101860. doi: 10.1016/j.eclinm.2023.101860. eCollection 2023 Mar.